NFE2L2 and metabolic dysfunction-associated steatohepatitis: Despite of critical findings illustrating the beneficial effects of CB1 receptor antagonist on hepatic fat inflammation, inflammation, and cell death at least partial involvement of increased Nrf2-AMPK pathway, animal model used in the present study did not develop NASH.